drugset / Trial / NCT00427414
Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma
Phase 1
Terminated
14 enrolled
AIDS Malignancy Consortium
National Cancer Institute (NCI) · collabThe Emmes Company, LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as liposomal daunorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying how well liposomal daunorubicin works in treating patients with HIV-related Kaposi's sarcoma.
Timeline
- Start
- 2008-09
- Primary completion
- 2010-11
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daunorubicin | Small molecule | 40 mg/m2 | Intravenous |